

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. BOX 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/766,752	01/27/2004	Darrell H. Carney	3033.1008-008	2963
21005 75	590 10/20/2004		EXAMINER	
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.			MONDESI, ROBERT B	
530 VIRGINIA	ROAD			
P.O. BOX 9133	3		· ART UNIT	PAPER NUMBER
CONCORD, MA 01742-9133			1653	
			D	

DATE MAILED: 10/20/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/766,752	CARNEY, DARRELL H.	
Office Action Summary	Examiner	Art Unit	
	Robert B Mondesi	1653	
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the o	correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tir y within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from t, cause the application to become ABANDONE	nely filed /s will be considered timely. In the mailing date of this communication. ED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on	<u>_</u> .		
	action is non-final.		
3) Since this application is in condition for alloward closed in accordance with the practice under E	·		
Disposition of Claims			
4) ⊠ Claim(s) 1-34 is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-34 are subject to restriction and/or of	wn from consideration.		
Application Papers			
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document: 2. Certified copies of the priority document: 3. Copies of the certified copies of the priority document: application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage	
Attachment(s)			
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da	ate Patent Application (PTO-152)	

Art Unit: 1653

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

The inventions are distinct, each from the other because of the following reasons:

This application contains claims directed to the following patentably distinct compounds of the claimed invention: In **claims**, **1-4**, the ability to substitute a variety of independently selected moieties in positions R₁ and R₂, has given rise to a multitude of peptide compounds. Each one of these compounds is patentably distinct absent factual evidence to the contrary.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed moiety in positions R₁ and R₂, that is searchable for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, the moieties selected in positions R₁ and R₂, are set forth in a series of alternatives.

Applicant is advised that a reply to this requirement must include a single moiety in positions R₁ and R₂, that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Restriction Requirement Applicable to all Groups

Furthermore, in claims 5, 8, 11, 14, 18, 21-22, 32 and 34 the presence of multiple polypeptide sequences, each with a different SEQ ID NO: allows for a variety of

Application/Control Number: 10/766,752

Art Unit: 1653

patentably distinct products. Depending on the sequence of each polypeptide the characteristics of the resulting molecule will vary in regards to structure and function. Each one of these polypeptides is capable of eliciting a specific immune response and can be used to produce a specific antibody. Therefore these polypeptides are patentably distinct absent factual evidence to the contrary. Applicant is required under 35 U.S.C. 121 to elect a single SEQ ID NO: for prosecution on the merits.

Applicant is advised that a reply to this requirement must include an identification of SEQ ID NO: that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. The applicant should be aware that selection of a single SEQ ID NO; represents a response to a restriction requirement, not an election of species.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, search, restriction for examination purposes as indicated is proper.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert B Mondesi whose telephone number is 571-272-0956. The examiner can normally be reached on 9am-5pm, Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/766,752

Art Unit: 1653

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Robert B. Mondesi Patent examiner Group 1653

> ROBERT A. WAX PRIMARY EXAMINER